Health and Healthcare

MicroRx: Infectious Disease Supercluster

From BioHealth Investor

by Adam Rubenstein

Colorado State University announced MicroRx, an entity designed to ally academia and commercial enterprise to ultimately accelerate the bench-to-bedside process. Infectious Disease is the focus of this first CSU Supercluster which was borne out of CSU Ventures, lead by Mark Wdowik.

CSU is an international center of excellence for the study of infectious disease. The university was recently awarded a $40M grant from the National Institute of Allergy and Infectious Diseases, $17M from the NIH for the Regional Biocontainment Lab, and the CDC’s $80M research lab on the CSU Foothills Campus just to name a few of the headline poppers. University foci include mycobacterial diseases like tuberculosis, vector borne disease like West Nile fever and malaria, retroviral diseases like AIDS, and prion diseases like chronic wasting disease. Other CSU projects focus upon antimicrobial resistance, development of new approaches to control mosquitoes, ticks and other disease-carrying arthropods and food safety.

MicroRx is designed to now aid the movement of research discoveries to the market.

http://www.biohealthinvestor.com/

Essential Tips for Investing: Sponsored

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.